Non-Hodgkin Lymphoma - Pipeline Review, H1 2020
Non-Hodgkin Lymphoma - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 2, 36, 203, 194, 4, 24, 172, 19 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages comprises 25, 29, 2, 1, 39, 4 and 1 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 2, 36, 203, 194, 4, 24, 172, 19 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages comprises 25, 29, 2, 1, 39, 4 and 1 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2020
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2020
Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2020
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2020
Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H1 2020
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2020
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2020
Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2020
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2020
Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H1 2020
LIST OF FIGURES
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
3SBio Inc
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
ABIONYX Pharma SA
Abologix Sarl
Abzena Ltd
ACEA Therapeutics Inc
Acerta Pharma BV
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
Adagene (Suzhou) Ltd
ADC Therapeutics SA
Adicet Bio Inc
Adienne Pharma & Biotech
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Affimed GmbH
Affitech A/S
Agenus Inc
Agios Pharmaceuticals Inc
AI Therapeutics
Akeso Inc
Aleta Biotherapeutics Inc
Alfasigma SpA
Alopexx Oncology LLC
ALX Oncology Inc
Amgen Inc
Anew Oncology Inc
Angimmune LLC
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp
AP Biosciences Inc
Apollomics Inc
Apotex Inc
Applied Therapeutics Inc
Aprea Therapeutics AB
Archigen Biotech Ltd
Argenx SE
Arrien Pharmaceuticals LLC
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AUM Biosciences Pte Ltd
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
Avipep Pty Ltd
AVM Biotechnology LLC
AzarGen Biotechnologies (Pty) Ltd
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Immunotech Applied Science Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BendaRx Corp
Betta Pharmaceuticals Co Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioEclipse Therapeutics Inc
Biogen Inc
BioIntegrator Ltd
BioInvent International AB
BioLineRx Ltd
Bioniz Therapeutics Inc
BioNTech SE
BioPact Ventures LLC
Biothera Pharmaceutical Inc
BioXpress Therapeutics SA
BiVictriX Therapeutics Ltd
bluebird bio Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Boryung ViGenCell Inc
Boston Biomedical Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cardiff Oncology Inc
Carrick Therapeutics Ltd
CARsgen Therapeutics Ltd
Cartherics Pty Ltd
CASI Pharmaceuticals Inc
Catalent Inc
Catapult Therapeutics BV
Celdara Medical LLC
Cell Source Inc
Cell>Point LLC
CellCentric Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Celltrion Inc
Cellular Biomedicine Group Inc
Cellular Biomedicine Group Ltd
Celularity Inc
Centaurus Biopharma Co Ltd
Centrose LLC
CerRx Inc
CGeneTech (Suzhou China) Co Ltd
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chengdu Brilliant Pharmaceutical Co Ltd
Children's National Research Institute
China Immunotech Co Ltd
Chipscreen Biosciences Ltd
CHO Pharma Inc
Chugai Pharmaceutical Co Ltd
Cielo Therapeutics Inc
Clayton Biotechnologies Inc
Clevexel Pharma SAS
Codiak BioSciences Inc
CoImmune Inc
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CrystalGenomics Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Daysai Biopharmaceuticals Inc
Debiopharm International SA
Decoy Biosystems Inc
Denovo Biopharma LLC
Dizal (Jiangsu) Pharmaceutical Co Ltd
Dr. Reddy's Laboratories Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Epidestiny Inc
Epizyme Inc
ERYTECH Pharma SA
Esanex Inc
Eternity Bioscience Inc
Eureka Therapeutics Inc
Eutilex Co Ltd
Evotec SE
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Galderma SA
Gamida Cell Ltd
GC Pharma
Geneius Biotechnology Inc
Genentech Inc
Geneos Therapeutics Inc
Generium
Generon (Shanghai) Corp Ltd
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
Genmab AS
Genor BioPharma Co Ltd
Genosco Inc
Gibson Oncology LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Gracell Biotechnology Ltd
Grupo Ferrer Internacional SA
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
H3 Biomedicine Inc
Hadasit Medical Research Services and Development Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
Helsinn Group
HRAIN Biotechnology Co Ltd
Hualan Biological Engineering Inc
Humanigen Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
iBio Inc
iCell Gene Therapeutics LLC
IGM Biosciences Inc
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
Immune Cell Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
ImmunoGen Inc
Immunomedics Inc
Immunomet Therapeutics Inc
Immunotech Biopharm Ltd
Impetis Biosciences Ltd
IMV Inc
Inatherys
Incuron LLC
Incyte Corp
Inflection Biosciences Ltd
Inhibrx Inc
Innate Pharma SA
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
IO Biotech ApS
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jazz Pharmaceuticals Plc
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
Jubilant Therapeutics Inc
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Therapeutics Shanghai Co Ltd
Kainos Medicine Inc
Kangpu Biopharmaceuticals Ltd
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kiniksa Pharmaceuticals Ltd
Kiromic BioPharma Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kronos Bio Inc
Kuur Therapeutics Ltd
Kymera Therapeutics LLC
Kyowa Kirin Co Ltd
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
3SBio Inc
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
ABIONYX Pharma SA
Abologix Sarl
Abzena Ltd
ACEA Therapeutics Inc
Acerta Pharma BV
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
Adagene (Suzhou) Ltd
ADC Therapeutics SA
Adicet Bio Inc
Adienne Pharma & Biotech
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Affimed GmbH
Affitech A/S
Agenus Inc
Agios Pharmaceuticals Inc
AI Therapeutics
Akeso Inc
Aleta Biotherapeutics Inc
Alfasigma SpA
Alopexx Oncology LLC
ALX Oncology Inc
Amgen Inc
Anew Oncology Inc
Angimmune LLC
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp
AP Biosciences Inc
Apollomics Inc
Apotex Inc
Applied Therapeutics Inc
Aprea Therapeutics AB
Archigen Biotech Ltd
Argenx SE
Arrien Pharmaceuticals LLC
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AUM Biosciences Pte Ltd
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
Avipep Pty Ltd
AVM Biotechnology LLC
AzarGen Biotechnologies (Pty) Ltd
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Immunotech Applied Science Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BendaRx Corp
Betta Pharmaceuticals Co Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioEclipse Therapeutics Inc
Biogen Inc
BioIntegrator Ltd
BioInvent International AB
BioLineRx Ltd
Bioniz Therapeutics Inc
BioNTech SE
BioPact Ventures LLC
Biothera Pharmaceutical Inc
BioXpress Therapeutics SA
BiVictriX Therapeutics Ltd
bluebird bio Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Boryung ViGenCell Inc
Boston Biomedical Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cardiff Oncology Inc
Carrick Therapeutics Ltd
CARsgen Therapeutics Ltd
Cartherics Pty Ltd
CASI Pharmaceuticals Inc
Catalent Inc
Catapult Therapeutics BV
Celdara Medical LLC
Cell Source Inc
Cell>Point LLC
CellCentric Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Celltrion Inc
Cellular Biomedicine Group Inc
Cellular Biomedicine Group Ltd
Celularity Inc
Centaurus Biopharma Co Ltd
Centrose LLC
CerRx Inc
CGeneTech (Suzhou China) Co Ltd
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chengdu Brilliant Pharmaceutical Co Ltd
Children's National Research Institute
China Immunotech Co Ltd
Chipscreen Biosciences Ltd
CHO Pharma Inc
Chugai Pharmaceutical Co Ltd
Cielo Therapeutics Inc
Clayton Biotechnologies Inc
Clevexel Pharma SAS
Codiak BioSciences Inc
CoImmune Inc
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CrystalGenomics Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Daysai Biopharmaceuticals Inc
Debiopharm International SA
Decoy Biosystems Inc
Denovo Biopharma LLC
Dizal (Jiangsu) Pharmaceutical Co Ltd
Dr. Reddy's Laboratories Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Epidestiny Inc
Epizyme Inc
ERYTECH Pharma SA
Esanex Inc
Eternity Bioscience Inc
Eureka Therapeutics Inc
Eutilex Co Ltd
Evotec SE
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Galderma SA
Gamida Cell Ltd
GC Pharma
Geneius Biotechnology Inc
Genentech Inc
Geneos Therapeutics Inc
Generium
Generon (Shanghai) Corp Ltd
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
Genmab AS
Genor BioPharma Co Ltd
Genosco Inc
Gibson Oncology LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Gracell Biotechnology Ltd
Grupo Ferrer Internacional SA
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
H3 Biomedicine Inc
Hadasit Medical Research Services and Development Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
Helsinn Group
HRAIN Biotechnology Co Ltd
Hualan Biological Engineering Inc
Humanigen Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
iBio Inc
iCell Gene Therapeutics LLC
IGM Biosciences Inc
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
Immune Cell Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
ImmunoGen Inc
Immunomedics Inc
Immunomet Therapeutics Inc
Immunotech Biopharm Ltd
Impetis Biosciences Ltd
IMV Inc
Inatherys
Incuron LLC
Incyte Corp
Inflection Biosciences Ltd
Inhibrx Inc
Innate Pharma SA
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
IO Biotech ApS
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jazz Pharmaceuticals Plc
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
Jubilant Therapeutics Inc
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Therapeutics Shanghai Co Ltd
Kainos Medicine Inc
Kangpu Biopharmaceuticals Ltd
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kiniksa Pharmaceuticals Ltd
Kiromic BioPharma Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kronos Bio Inc
Kuur Therapeutics Ltd
Kymera Therapeutics LLC
Kyowa Kirin Co Ltd
